A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study of the Efficacy and Safety of ALV003 Treatment in Symptomatic Celiac Disease Patients Maintained on a Gluten-Free Diet

Trial Profile

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study of the Efficacy and Safety of ALV003 Treatment in Symptomatic Celiac Disease Patients Maintained on a Gluten-Free Diet

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Latiglutenase (Primary)
  • Indications Coeliac disease
  • Focus Therapeutic Use
  • Acronyms CeliAction
  • Sponsors Alvine Pharmaceuticals
  • Most Recent Events

    • 28 Jul 2017 Results of a post hoc subgroup analysis published in the Digestive Diseases and Sciences
    • 09 May 2017 Results of subgroup analysis assessing effect of latiglutenase on specific symptoms of Coeliac-disease, presented at the Digestive Disease Week 2017
    • 02 May 2017 ImmunogenX added to assocoations since acquired rights for latiglutenase from Alvine Pharmaceuticals in March 2016 and is responsible for all future development and commercialisation activities.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top